Yi-Gan San as Adjunctive Therapy for Treatment-Resistant Schizophrenia: An Open-Label Study

Clinical Neuropharmacology

Volumn 32, Issue 1, 2009, Pages 6-9

  Miyaoka, Tsuyoshi ^a   Furuya, Motohide ^a   Yasuda, Hideaki ^a   Hayashida, Maiko ^a   Nishida, Akira ^a   Inagaki, Takuji ^a   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Adjunctive therapy open label, treatment resistant; Schizophrenia; Yi gan san

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; HERBACEOUS AGENT; LEVOMEPROMAZINE; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; YI GAN SAN; ZOTEPINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOM SCALE; FATIGUE; FEMALE; HERBAL MEDICINE; HUMAN; MALE; NAUSEA; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, KAMPO; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 67749114569     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31817e08c3     Document Type: Article

References (13)

1. Conley RR, Buchanan RV. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663-674.
2. Aizawa R, Kanbayashi T, Saito Y, et al. Effects of yoku-kan-san-ka-chipi- hange on the sleep of normal healthy adult subjects. Psychiatry Clin Neurosci 2002;56:303-304.
3. Iwasaki K, Satoh-Nakagawa T, Maruyama M. A randomized observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005;66:248-252.
4. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:150-154.
5. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:761-764.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
7. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
8. Inada T, Yagi G, Gardos G. Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS). In abstract of the 20th Collegium International. Neuropsychopharmacologium, Melbourne. 23-27.
9. Shimada Y, Goto H, Itoh T. Evaluation of the protective effects of alkaloids isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats. J Pharm Pharmacol 1999;51:715-722.
10. Liao JF, Jan YM, Huang SY. Evaluation with receptor binding assay on the water extracts of ten CNS-active Chinese herbal drugs. Proc Natl Sci Counc Repub China B 1995;19:151-158.
11. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293.
12. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drug: a review of components in use and developments. Br J Psychiatry 1993;163(Suppl 12):7-18.
13. Ishibashi A, Rgashira N, Mishima K, et al. Study on the central action of Yoku-kan-san [abstract in English]. Yakugaku Zasshi 2006;126(Suppl 2):82-84.